Biomarker for breast cancer malignant risk diagnosis and prognosis prediction and application thereof
By using KNSTRN mRNA as a biomarker, gene expression analysis and siRNA knockdown experiments were carried out, the problem of prognosis prediction of breast cancer and TNBC was solved, and the accurate diagnosis and identification of TNBC was achieved, and the therapeutic targets were improved, which improved the therapeutic effect and individualization were improved. Feasibility of treatment.
Patent Information
- Application Number
- CN202411096409.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
AI Technical Summary
The lack of effective biomarkers in the prior art for the prognosis prediction of breast cancer and triple-negative breast cancer (TNBC), resulting in delayed diagnosis, difficult treatment, poor prognosis, insufficient individualized treatment, and lack of targeted treatment, resulting in patients Psychological and social health has been significantly affected.
KNSTRN mRNA was used as a biomarker to evaluate its immune infiltration in TNBC through gene expression differences, clinical correlation, prognostic value assessment and functional enrichment analysis, and its malignancy in TNBC cancer cells was studied by knocking down KNSTRN by siRNA. The impact of phenotype provides methods for diagnosis and prognosis of breast cancer malignant risk.
Accurate diagnostic typing and prognosis prediction of TNBC are achieved, providing a basis for assisting clinical decision-making, and providing important significance for the development of new TNBC therapeutic targets, improving the accuracy and effectiveness of treatment choices.
Smart Images

Figure CN118995924A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine and medical detection technology, and specifically to biomarkers and applications thereof for diagnosis of malignancy risk and prognosis prediction of breast cancer. Background Art
[0002] Breast cancer is the most common malignancy in women worldwide and the leading cause of cancer-related death in women. Despite some progress in surgery, radiotherapy, chemotherapy and endocrine therapy in recent years, the prognosis of breast cancer, especially triple-negative breast cancer (TNBC) patients, remains unsatisfactory. TNBC is an aggressive subtype of breast cancer characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBC usually occurs in young premenopausal women under 40 years old, accounting for about 15-20% of all breast cancer patients, leading to poor outcomes in actual clinical practice. Compared with other subtypes, TNBC patients have a shorter survival time and higher mortality rate, with a 40% risk of death within five years of diagnosis;
[0003] The diagnosis of breast cancer is usually based on imaging examinations, biopsies, and pathological evaluations. Due to the lack of ER, PR, and HER2 expression in TNBC, the diagnosis must be confirmed by immunohistochemistry. Treatment includes surgery, radiotherapy, and chemotherapy. TNBC has a relatively poor prognosis due to the lack of targeted therapy, and is prone to recurrence and metastasis. Due to the lack of biomarkers that can be used to predict the prognosis of breast cancer and TNBC, it is impossible to provide effective clinical advice, and the diagnosis is delayed due to the lack of obvious early symptoms. At the same time, TNBC lacks targeted therapy, chemotherapy and radiotherapy have significant side effects, high recurrence rate, poor prognosis, insufficient individualized treatment, and a heavy economic burden, which has a significant impact on the patient's psychosocial health;
[0004] KNSTRN is a protein-coding gene that is highly concentrated at the centromere from prometaphase to anaphase and plays a key role in ensuring the correct division of cells. Recent studies have identified KNSTRN as a potential oncogene involved in the progression of multiple cancers, however, there is currently a lack of research confirming its correlation with the malignant characteristics and immune infiltration of TNBC;
[0005] In modern scientific research, bioinformatics has revolutionized the diagnosis and treatment of breast cancer, significantly improving the efficiency and effectiveness of clinical management. Using bioinformatics to analyze large amounts of gene expression data can help identify key prognostic markers. Reliable biomarkers can be used for early diagnosis, accurate stratification of patient risk, and guidance for the development of personalized treatment plans. They can also predict a patient's response to a specific treatment, provide potential targets for the development of new drugs, and help reduce unnecessary treatments, reduce the burden on patients, and improve survival rates. To this end, new technical solutions need to be designed to address this problem. Summary of the invention
[0006] The purpose of the present invention is to provide a biomarker for diagnosis of malignancy risk and prognosis prediction of breast cancer and its application, which solves the problems raised in the background technology.
[0007] To achieve the above-mentioned purpose, the present invention provides the following technical solution: a biomarker for diagnosis of malignancy risk and prognosis prediction of breast cancer, comprising: KNSTRN mRNA.
[0008] The present invention also relates to the application of biomarkers for breast cancer malignancy risk diagnosis and prognosis prediction, including the following operations:
[0009] Gene expression differences, clinical relevance, prognostic value assessment, and functional enrichment analysis of KNSTRN in TNBC;
[0010] Immune infiltration analysis of KNSTRN in TNBC;
[0011] The effect of knockdown of KNSTRN by siRNA on the malignant phenotype of TNBC cancer cells was evaluated.
[0012] As a preferred embodiment of the present invention, the gene expression difference, clinical relevance, prognostic value evaluation and functional enrichment analysis of KNSTRN in TNBC include the following methods:
[0013] This study utilized transcriptome sequencing data of 360 primary TNBC tumor tissues downloaded from the European Nucleotide Archive database TNBC dataset SRP157974, the breast cancer dataset METABRIC (2509 breast cancers, including 320 TNBCs) downloaded from the cBioPortal database, and the TNBC dataset GSE76250 downloaded from the Gene Expression Omnibus database, including microarray data of 165 TNBC primary tumor tissues and 33 adjacent normal tissues, including 33 pairs of matched TNBC tumor and adjacent non-tumor samples.
[0014] ROC curves and Youden index were used to calculate the cutoff values for distinguishing TNBC from non-TNBC patients.
[0015] The RNA sequencing data were analyzed using the Wilcoxon rank sum test and the Wilcoxon signed rank test to determine the differences in KNSTRN expression between multiple groups and paired samples.
[0016] The Wilcoxon rank-sum test was used to evaluate the prognostic significance of KNSTRN expression in various clinicopathological characteristics (including PAM50, ER status, PR status, pathological stage, and T stage).
[0017] Kaplan-Meier survival analysis was performed using the “survival” and “survminer” packages, with the cutoff value of KNSTRN expression set to the median to investigate its association with recurrence-free survival (RFS).
[0018] TNBC patients in the METABRIC cohort were divided into two groups according to the expression level of KNSTRN. GSVA and GSEA were performed using the hallmark gene set from the MSigDB database. The linear model in the limma software package was used to evaluate the enrichment significance of the hallmark gene set in GSVA.
[0019] As a preferred embodiment of the present invention, the immune infiltration analysis of KNSTRN in TNBC includes the following method:
[0020] The ssGSEA method in the GSVA package was used to evaluate the correlation between KNSTRN and the characteristic genes of 24 different immune cell types. The Spearman correlation method was used to evaluate the correlation between KNSTRN and the above 24 immune cell types. The Wilcoxon rank sum test was used to compare the immune cell infiltration between the KNSTRN high expression group and the low expression group.
[0021] The breast cancer single-cell transcriptome dataset GSE176078 was downloaded from the Gene Expression Omnibus database. The dataset contained single-cell transcriptome sequencing data of tumor tissues from 11 ER+, 5 HER2+ and 10 TNBC patients. The scRNA-seq data were analyzed using R software and Seurat software package. Canonical correlation analysis (CCA) was used to integrate multiple single-cell samples. The first 20 principal components were used for UMAP dimensionality reduction, and the SNN graph was constructed. The Louvain algorithm with a resolution of 0.8 was used for cell clustering analysis.
[0022] As a preferred embodiment of the present invention, evaluating the effect of knocking down KNSTRN by siRNA on the malignant phenotype of TNBC cancer cells includes the following method:
[0023] The MDA-MB-231 human breast cancer cell line was obtained from the BeNa cell bank and cells were cultured in a 37°C incubator containing 5% CO2 using Dulbecco's modified Eagle's high glucose growth medium supplemented with 10% FBS and 1% penicillin and streptomycin.
[0024] MDA-MB-231 cells were grown in six-well plates and used when the growth density reached 50%. The cells were incubated for 48 h after transfection to ensure effective knockdown of KNSTRN.
[0025] Cellular proteins were extracted using RIPA buffer, and protein concentrations were determined using a BCA protein quantification kit. Equal amounts of protein were separated by SDS-PAGE using 10% polyacrylamide gel, and the separated proteins were transferred to a PVDF membrane using a constant voltage (100 V) for approximately 60 minutes. After the membrane was blocked with 5% milk for 2 hours, it was incubated with the primary antibody at 4°C overnight. The membrane was washed three times and incubated with the secondary antibody at room temperature for 1 hour. The primary antibodies were KNSTRN antibody and GAPDH antibody. ECL luminescent reagent was added to the membrane, and the protein bands were visualized using an imaging system. The relative expression levels of the target proteins were quantified using ImageJ software.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The present invention provides a method for the diagnosis and prognosis prediction of TNBC, which is of great significance for early evaluation of the prognosis of TNBC, assisting clinical decision-making, and developing new TNBC treatment targets.
[0028] According to an embodiment of the present invention, the application of the marker in diagnosing breast cancer patients as TNBC is based on the expression of the patient's KNSTRN mRNA. The expression level of KNSTRN is calculated by log2(TPM+1), and the expression level threshold is 4.565. The accuracy of distinguishing TNBC and non-TNBC patients based on this threshold is 73.3%.
[0029] According to an embodiment of the present invention, the application of the TNBC marker in screening TNBC treatment methods or therapeutic drugs is based on the expression of KNSTRN mRNA in TNBC patients. When the KNSTRN mRNA expression level is higher, it means that the possibility of further deterioration of the tumor tissue of the TNBC patient after receiving relevant treatment is higher, the screened treatment method or therapeutic drug does not effectively control the development of the tumor, and the treatment method or therapeutic drug is improperly selected; when the KNSTRN mRNA expression level increases, it means that the occurrence and development of the tumor tissue of the TNBC patient after receiving relevant treatment is effectively controlled, the screened treatment method or therapeutic drug is reasonably selected, and the disease is effectively treated. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0031] Figure 1 is the expression level diagram of KNSTRN in TNBC;
[0032] Figure 2 is the correlation diagram between KNSTRN expression and clinicopathological characteristics;
[0033] Figure 3 is the functional enrichment analysis diagram of KNSTRN-related DEGs;
[0034] Figure 4 This is a diagram of the relationship between KNSTRN and immune cells in TNBC;
[0035] Figure 5 This is a graph of KNSTRN expression levels in TNBC analyzed based on single-cell sequencing data;
[0036] Figure 6 KnSTRN knockdown suppressed the malignant characteristics of TNBC cells. DETAILED DESCRIPTION
[0037] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.
[0038] See also Figure 1-6 In one aspect of the present invention, the present invention proposes biomarkers for diagnosis and prognosis prediction of TNBC. According to an embodiment of the present invention, the biomarkers include but are not limited to KNSTRN mRNA.
[0039] In another aspect of the present invention, a new method for diagnosing breast cancer patients as TNBC is proposed. According to an embodiment of the present invention, the expression level of KNSTRN is calculated by log2(TPM+1), and the expression level threshold is 4.565. The accuracy of distinguishing TNBC and non-TNBC patients based on this threshold is 73.3%.
[0040] In yet another aspect of the present invention, the present invention provides a new method for evaluating the prognosis of TNBC. According to an embodiment of the present invention, the prognosis of TNBC patients can be evaluated using the above biomarkers.
[0041] In another aspect of the present invention, the present invention discloses a potential target KNSTRN for TNBC immunotherapy. According to the embodiments of the present invention, KNSTRN is closely related to key immune cells in the TNBC immune microenvironment, indicating its importance in the immune function of TNBC.
[0042] In another aspect of the present invention, the present invention provides a kit for detecting the therapeutic effect of TNBC, comprising a reagent for detecting KNSTRN mRNA and instructions for use. The progression and prognosis of tumor tissue in TNBC patients can be determined by the expression of KNSTRN.
[0043] To study the expression and prognostic analysis of KNSTRN in TNBC, the inventors conducted research through gene expression difference analysis, clinical feature correlation, prognostic value assessment, functional enrichment analysis, immune infiltration analysis, and functional verification after siRNA knockdown.
[0044] The scheme of the present invention will be explained below in conjunction with examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.
[0045] Example 1
[0046] Gene expression differences, clinical relevance, prognostic value assessment and functional enrichment analysis of KNSTRN in TNBC.
[0047] The specific method is as follows:
[0048] This study utilized transcriptome sequencing data of 360 primary TNBC tumor tissues downloaded from the European Nucleotide Archive database TNBC dataset SRP157974, the breast cancer dataset METABRIC (2509 breast cancers, including 320 TNBCs) downloaded from the cBioPortal database, and the TNBC dataset GSE76250 downloaded from the Gene Expression Omnibus database, including microarray data of 165 TNBC primary tumor tissues and 33 adjacent normal tissues, including 33 pairs of matched TNBC tumor and adjacent non-tumor samples.
[0049] ROC curves and Youden index were used to calculate the cutoff values for distinguishing TNBC from non-TNBC patients.
[0050] The RNA sequencing data were analyzed using the Wilcoxon rank sum test and the Wilcoxon signed rank test to determine the differences in KNSTRN expression between multiple groups and paired samples.
[0051] The Wilcoxon rank-sum test was used to evaluate the prognostic significance of KNSTRN expression in various clinicopathological characteristics (including PAM50, ER status, PR status, pathological stage, and T stage).
[0052] Kaplan-Meier survival analysis was performed using the “survival” and “survminer” packages, with the cutoff value of KNSTRN expression set to the median to investigate its association with recurrence-free survival (RFS).
[0053] TNBC patients in the METABRIC cohort were divided into two groups according to the expression level of KNSTRN. GSVA and GSEA were performed using the hallmark gene set from the MSigDB database. The linear model in the limma software package was used to evaluate the enrichment significance of the hallmark gene set in GSVA.
[0054] The results are as follows:
[0055] like Figure 1 As shown, according to the embodiment of the present invention, the expression level of KNSTRN is significantly upregulated in TNBC compared with other breast cancer subtypes ( Figure 1 A), the expression level of KNSTRN was calculated by log2(TPM+1), and the expression threshold was 4.565. The accuracy of distinguishing TNBC and non-TNBC patients based on this threshold was 73.3% ( Figure 1 B), up-regulated expression of KNSTRN in FUSCC ( Figure 1 C) and PAM50( Figure 1 D) was further confirmed in the subtypes classified under this classification. In addition, the inventors selected a GEO dataset (GSE76250) for verification and obtained consistent results ( Figure 1 E and 1F).
[0056] like Figure 2 As shown, according to the embodiment of the present invention, the inventors analyzed the expression data of KNSTRN and patient characteristics, and the data showed that the expression of KNSTRN was significantly correlated with PAM50 (P<0.01, Figure 2 A), ER status (P<0.001, Figure 2 B), PR status (P<0.001, Figure 2 C), pathological stage (P<0.05, Figure 2 D) and T stage (P<0.001, Figure 2 E) is significantly correlated in breast cancer. This suggests that KNSTRN may play an important role in more malignant breast cancer subtypes. The Kaplan-Meier method was used to evaluate the association between KNSTRN expression and the prognosis of breast cancer patients. Patients were divided into high KNSTRN expression group and low KNSTRN expression group according to the median value of KNSTRN expression level. Compared with the low KNSTRN expression group, patients with high KNSTRN expression level showed poor recurrence-free survival (RFS, HR=1.42, p<0.05, Figure 2 F).
[0057] like Figure 3 As shown, according to an embodiment of the present invention, the differentially expressed genes associated with KNSTRN were screened by applying the cutoff criteria of |logFC|<1.5 and corrected p<0.05, and GSVA ( Figure 3 A) and GSEA( Figure 3 B) Enrichment analysis of KNSTRN-related DEGs in TNBC showed that pathways such as DNA repair, MYC targets, E2F targets, G2M checkpoints, Mitotic spindle, Glycolysis, and mTORC1 signaling were activated in TNBC patients with high KNSTRN expression. The results indicate that pathways regulating tumor cell growth, proliferation, and metabolism are significantly associated with high KNSTRN expression in breast cancer.
[0058] Example 2
[0059] Immune infiltration analysis of KNSTRN in TNBC
[0060] The specific method is as follows:
[0061] The ssGSEA method in the GSVA package was used to evaluate the correlation between KNSTRN and the characteristic genes of 24 different immune cell types. The Spearman correlation method was used to evaluate the correlation between KNSTRN and the above 24 immune cell types. The Wilcoxon rank sum test was used to compare the immune cell infiltration between the KNSTRN high expression group and the low expression group.
[0062] The breast cancer single-cell transcriptome dataset GSE176078 was downloaded from the Gene Expression Omnibus database. The dataset contained single-cell transcriptome sequencing data of tumor tissues from 11 ER+, 5 HER2+ and 10 TNBC patients. The scRNA-seq data were analyzed using R software and Seurat software package. Canonical correlation analysis (CCA) was used to integrate multiple single-cell samples. The first 20 principal components were used for UMAP dimensionality reduction, and the SNN graph was constructed. The Louvain algorithm with a resolution of 0.8 was used for cell clustering analysis.
[0063] The results are as follows:
[0064] like Figure 4 As shown, according to the embodiment of the present invention, in the TNBC immune microenvironment, KNSTRN showed significant correlation with many immune cells ( Figure 4 ), the expression of KNSTRN was significantly positively correlated with the immune cell infiltration level of Activated CD4 T cell. The expression of KNSTRN was significantly positively correlated with Immature dendritic cell,Immature B cell,CD56 brightnatural killer cell,Central memory CD8 Tcell,Mast cell,MDSC,Activated CD8 Tcell,Macrophage,Monocyte,Type 17T helper cell,Central memory CD4 Tcell,Activated B cell,Plasmacytoid dendritic cell,CD56 dim natural killer cell,
[0065] The immune cell infiltration levels of Type1T helper cell,Natural killer cell,Tfollicular helper cell,Eosinophil,Effector memory CD8 T cell were significantly negatively correlated.
[0066] like Figure 5 As shown, according to an embodiment of the present invention, the inventors analyzed the TNBC single cell dataset. Figure 5 A shows the integration of all samples of 26 primary tumor samples including 11 ER+, 5 HER2+ and 10 TNBCs, showing good integration and no obvious batch effect. The analysis revealed a total of 29 different cell types in breast cancer, of which the top five most abundant were T cells CD4+, T cells CD8+, Cancer LumA SC, Macrophages, CancerCycling ( Figure 5 B), compared with the other two subtypes, significant changes were observed in the proportions of Cancer Basal SC, Cancer Cycling, Macrophages, T cells CD4+, and T cells CD8+ in TNBC ( Figure 5 C), Analysis of KNSTRN expression in different cell types in three breast cancer subtypes revealed upregulation of KNSTRN in TNBC, especially in Cancer Cycling cells, Cancer Basal SC, Macrophages, and T cells ( Figure 5 D), CancerCycling cells refer to malignant cells that actively undergo the cell cycle. They have a high proliferative capacity and serve as the main driver of tumor growth and progression. Cancer Basal SC represents the basal-like subtype of breast cancer cells, which is associated with increased invasiveness and poor prognosis. Macrophages, as part of the immune system, have the ability to promote tumor growth and metastasis in breast cancer. T cells are a key component of the adaptive immune system and are generally associated with a better prognosis and a good response to immunotherapy. Overall, these results indicate a clear correlation between KNSTRN expression and the immune function and malignant characteristics of TNBC.
[0067] Example 3
[0068] The specific methods for evaluating the effect of knockdown of KNSTRN by siRNA on the malignant phenotype of TNBC cancer cells are as follows:
[0069] The MDA-MB-231 human breast cancer cell line was obtained from the BeNa cell bank and cells were cultured in a 37°C incubator containing 5% CO2 using Dulbecco's modified Eagle's high glucose growth medium supplemented with 10% FBS and 1% penicillin and streptomycin.
[0070] MDA-MB-231 cells were grown in six-well plates and used when the growth density reached 50%. The cells were incubated for 48 h after transfection to ensure effective knockdown of KNSTRN.
[0071] Cellular proteins were extracted using RIPA buffer. Protein concentration was determined using a BCA protein quantification kit, and equal amounts of protein were separated by SDS-PAGE using 10% polyacrylamide gel. The separated proteins were transferred to a PVDF membrane using a constant voltage (100 V) for approximately 60 minutes. After the membrane was blocked with 5% milk for 2 hours, it was incubated with the primary antibody at 4°C overnight. The membrane was washed three times and incubated with the secondary antibody at room temperature for 1 hour. The primary antibodies were KNSTRN antibody and GAPDH antibody. ECL luminescent reagents were added to the membrane, and the protein bands were visualized using an imaging system. The relative expression levels of the target proteins were quantified using ImageJ software.
[0072] After knocking down KNSTRN, cells were seeded at a density of 1×10^5 in a six-well plate. When the cell density reached 80%, scratches were made using a 200 μL pipette tip, and images of cell scratches were taken using a microscope (magnification, ×10) at 0, 24, and 48 hours. The width of the scratches was measured using ImageJ software.
[0073] A Transwell chamber with a pore size of 8.0 μm was placed in a well of a 12-well plate, and 3×10^5 cells were added to the upper chamber in 500 μL of serum-free medium, while 1 mL of medium containing 10% FBS was added to the lower layer. After incubation at 37°C, the chamber was removed, the excess medium was discarded, and the cells that did not migrate on the upper surface of the chamber were gently wiped with a wet cotton swab. The cells that migrated to the lower surface of the chamber were fixed with 4% formaldehyde and stained with 0.5% crystal violet solution at room temperature for 10 minutes. Images of the migrating cells were taken with a microscope, and five fields of view with a magnification of 100× were randomly selected to count and analyze the number of cells that passed through the hole.
[0074] MDA-MB-231 cells were transfected with siKNSTRN or siControl. After 24 hours, the cells were collected and seeded in 24-well plates. The next day, the EdU in vitro kit was used for the experiment. 50 μM EdU was added to the cells. After 2 hours of incubation, EdU was detected using Apollo staining solution, and the nuclei of all cells were stained with Hoechst 33342 staining solution. Fluorescence microscopy was used to take pictures and the proliferation rate was calculated by analyzing the ratio of EdU positive cells to the total number of cells using ImageJ software.
[0075] The results are as follows:
[0076] like Figure 6As shown, according to the embodiment of the present invention, the MDA-MB-231 cell line was transfected with siRNA targeting KNSTRN to study the effect of KNSTRN in TNBC, and the knockdown efficiency of siKNSTRN#1, siKNSTRN#2 and siKNSTRN#3 was verified by Western blot ( Figure 6 A), among the siRNAs used, siKNSTRN#3 showed better silencing efficiency than siKNSTRN#1 and siKNSTRN#2 and was used in subsequent experiments. EdU is a thymine analog that can replace thymine during DNA replication and integrate into the extending DNA chain. The unique interaction between Apollo fluorescent dye and EdU can directly and accurately detect DNA replication activity. EdU experiments showed that compared with the control group, the DNA synthesis activity in the KNSTRN knockdown group cells was significantly reduced ( Figure 6 B), In addition, the inventors evaluated the effect of KNSTRN on breast cancer cell migration ability, wound healing (p < 0.05, Figure 6 C and 6D) and Transwell assay (p<0.05, Figure 6 E and 6F) results showed that the migration potential of MDA-MB-231 cells was significantly reduced after siKNSTRN treatment. Overall, the examples show that silencing KNSTRN effectively inhibits the proliferation and migration of MDA-MB-231 cells, highlighting the potential pro-cancer role of KNSTRN in TNBC and emphasizing its prospect as a diagnostic and prognostic marker as well as a therapeutic target.
Claims
1. A biomarker for breast cancer malignancy risk diagnosis and prognosis prediction, characterized in that: include: KNSTRNmRNA.
2. The use of a biomarker for diagnosis of malignant risk and prognosis prediction of breast cancer is applicable to the biomarker for diagnosis of malignant risk and prognosis prediction of breast cancer according to claim 1, characterized in that: The following operations are included: Gene expression differences, clinical relevance, prognostic value assessment, and functional enrichment analysis of KNSTRN in TNBC; Immune infiltration analysis of KNSTRN in TNBC; The effect of knockdown of KNSTRN by siRNA on the malignant phenotype of TNBC cancer cells was evaluated.
3. The use of a biomarker for breast cancer malignancy risk diagnosis and prognosis prediction according to claim 2, characterized in that: The gene expression difference, clinical relevance, prognostic value assessment and functional enrichment analysis of KNSTRN in TNBC include the following methods: The transcriptome sequencing data of 360 primary TNBC tumor tissues downloaded from the European Nucleotide Archive database TNBC dataset SRP157974, the breast cancer dataset METABRIC downloaded from the cBioPortal database, and the TNBC dataset GSE76250 downloaded from the Gene Expression Omnibus database, including microarray data of 165 TNBC primary tumor tissues and 33 adjacent normal tissues, including 33 pairs of matched TNBC tumor and adjacent non-tumor samples; ROC curve and Youden index were used to calculate the cutoff value for distinguishing TNBC and non-TNBC patients; RNA sequencing data were analyzed using Wilcoxon rank sum test and Wilcoxon signed rank test to determine the differences in KNSTRN expression between multiple groups and paired samples; The Wilcoxon rank-sum test was used to evaluate the prognostic significance of KNSTRN expression in various clinicopathological characteristics, including PAM50, ER status, PR status, pathological stage, and T stage; Kaplan-Meier survival analysis was performed using the "survival" and "survminer" packages, with the cutoff value of KNSTRN expression set to the median to determine its association with recurrence-free survival; TNBC patients in the METABRIC cohort were divided into two groups according to the expression level of KNSTRN. GSVA and GSEA were performed using the hallmark gene set from the MSigDB database. The linear model in the limma software package was used to evaluate the enrichment significance of the hallmark gene set in GSVA.
4. The use of a biomarker for breast cancer malignancy risk diagnosis and prognosis prediction according to claim 2, characterized in that: Immune infiltration analysis of KNSTRN in TNBC includes the following methods: The s sGSEA method in the GSVA package was used to evaluate the correlation between KNSTRN and the characteristic genes of 24 different immune cell types. The Spearman correlation method was used to evaluate the correlation between KNSTRN and the above 24 immune cell types. The Wilcoxon rank sum test was used to compare the immune cell infiltration between the KNSTRN high expression group and the low expression group. The breast cancer single-cell transcriptome dataset GSE 176078 was downloaded from the Gene Expression Omnibus database. The dataset contained single-cell transcriptome sequencing data of tumor tissues from 11 ER+, 5 HER2+ and 10 TNBC patients. The scRNA-seq data were analyzed using R software and Seurat software package. Multiple single-cell samples were integrated using canonical correlation analysis. The first 20 principal components were used for UMAP dimensionality reduction, and the SNN graph was constructed. The Louvain algorithm with a resolution of 0.8 was used for cell clustering analysis.
5. The use of a biomarker for breast cancer malignancy risk diagnosis and prognosis prediction according to claim 2, characterized in that: Evaluation of the effect of knockdown of KNSTRN by siRNA on the malignant phenotype of TNBC cancer cells, including the following methods: The MDA-MB-231 human breast cancer cell line was obtained from the BeNa cell bank, and the cells were cultured in a 37°C incubator containing 5% CO using Dulbecco's modified Eagle's high-glucose growth medium supplemented with 10% FBS and 1% penicillin and streptomycin; MDA-MB-231 cells were grown in six-well plates and used when the growth density reached 50%. Transfection reagent was used for transfection, and cells were incubated for 48 h after transfection to ensure effective knockdown of KNSTRN; Cellular proteins were extracted using RIPA buffer, and protein concentrations were determined using a BCA protein quantification kit. Equal amounts of protein were separated by SDS-PAGE using 10% polyacrylamide gel, and the separated proteins were transferred to a PVDF membrane using a constant voltage for approximately 60 minutes. After the membrane was blocked with 5% milk for 2 hours, it was incubated with the primary antibody overnight at 4°C. The membrane was washed three times and incubated with the secondary antibody at room temperature for 1 hour. The primary antibodies were KNSTRN antibody and GAPDH antibody. ECL luminescent reagent was added to the membrane, and the protein bands were visualized using an imaging system. The relative expression levels of the target proteins were quantified using ImageJ software.
